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Abstract
 
Plasmacytoid dendritic cells are present in lymphoid and nonlymphoid tissue and contribute
substantially to both innate and adaptive immunity. Recently, we have described several
monoclonal antibodies that recognize a plasmacytoid dendritic cell-specific antigen, which we
have termed BDCA-2. Molecular cloning of BDCA-2 revealed that BDCA-2 is a novel type
II C-type lectin, which shows 50.7% sequence identity at the amino acid level to its putative
murine ortholog, the murine dendritic cell–associated C-type lectin 2. Anti–BDCA-2 mono-
clonal antibodies are rapidly internalized and efficiently presented to T cells, indicating that
BDCA-2 could play a role in ligand internalization and presentation. Furthermore, ligation of
BDCA-2 potently suppresses induction of interferon 
 
 
 
/
 
  
 
production in plasmacytoid dendritic
cells, presumably by a mechanism dependent on calcium mobilization and protein-tyrosine
phosphorylation by src-family protein-tyrosine kinases. Inasmuch as production of interferon
 
 
 
/
 
 
 
 by plasmacytoid dendritic cells is considered to be a major pathophysiological factor in sys-
temic lupus erythematosus, triggering of BDCA-2 should be evaluated as therapeutic strategy
for blocking production of interferon 
 
 
 
/
 
 
 
 in systemic lupus erythematosus patients.
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Introduction
 
Plasmacytoid dendritic cells (PDCs),
 
*
 
 which are also
known as plasmacytoid T cells (1), plasmacytoid mono-
cytes (2), natural IFN-
 
 
 
/
 
 
 
–producing cells (natural IPCs;
references 3–10), and type 2 predendritic cells (pDC2; ref-
erences 11–14), constitute a subset of immature dendritic
cells (DCs), which is capable of differentiating in vitro into
mature DCs with typical dendritic cell morphology and
potent T cell stimulatory function when exposed to IL-3
alone (15–17), IL-3 and CD40L (18, 19), viruses (20, 21),
and bacterial DNA containing unmethylated CpG motifs
(CpG-DNA; references 14 and 22). Immature PDCs have
been found in human LN (23), tonsils (18, 24), peripheral
blood (16, 17, 19, 24–27), cord blood (13, 28), adult and
fetal thymus (13, 29–31), fetal liver (13), and fetal bone
marrow (13, 24). In addition, presence of PDCs in affected
and sometimes even nonaffected tissue has been described
in association with many pathological circumstances, in-
cluding granulomatous lymphadenitis (32), Kikuchi’s lymph-
 
A. Dzionek, Y. Sohma, and J. Nagafune contributed equally to this work.
Y. Yamaguchi and J. Schmitz share senior authorship for this work.
 
Address correspondence to J. Schmitz, Miltenyi Biotec GmbH, Friedrich-
Ebert-Strabe 68, D-51429 Bergisch Gladbach, Germany. Phone: 49-2204-
8306-410; Fax: 49-2204-85197; E-mail: juergenS@miltenyibiotec.de
 
*
 
Abbreviations used in this paper:
 
 CRD, carbohydrate recognition do-
main; DC, dendritic cell; DCIR, human DC immunoreceptor; dectin-2,
DC-associated C-type lectin 2; ds, double-stranded; FLU, influenza
A/PR8 virus; PDC, plasmacytoid dendritic cell; RT, reverse transcrip-
tion; SLE, systemic lupus erythematosus; ss, single-stranded; TBE, Tris-
borate-EDTA; TLR9, toll-like receptor 9. 
1824
 
BDCA-2, a PDC-specific Type II C-type Lectin
 
adenitis (33), dermal lesions and noninflammatory skin
of systemic lupus erythematosus (SLE) patients (34, 35),
benign cutaneous lymphoid infiltrates (36, 37), nasal mu-
cosa of allergic as well as nonallergic individuals (38), and
cerebrospinal fluid from patients with inflammatory as well
as noninflammatory neurological diseases (39). Identifica-
tion of immature PDCs in blood has been commonly
based on a multitude of immunophenotypic criteria, such
as the absence of CD11c, ILT-1, and a panel of leukocyte
lineage-specific Ags (e.g., CD3, CD14, CD19, and CD56)
and the presence of CD4, CD123, HLA-DR, CD68,
ILT3, or CD45RA (10, 16, 17, 24–27). However, using a
panel of new mAb raised against blood DCs, we have re-
cently identified two novel markers of PDCs (19), BDCA-2
and BDCA-4, which enable direct identification of PDCs
in human blood. Here we describe the molecular and
functional characterization of BDCA-2. BDCA-2 is a
novel type II C-type lectin presumably involved in ligand
internalization, processing and presentation, as well as in
inhibition of IFN-
 
 
 
/
 
  
 
synthesis in PDCs. Our results
identify BDCA-2 as an attractive pharmaceutical target for
specific downmodulation of IFN-
 
 
 
/
 
  
 
expression in pa-
tients with SLE.
 
Materials and Methods
 
Cell Preparations.
 
Buffy coats from normal healthy volunteers
were obtained from the Institute for Transfusion Medicine, Mer-
heim Hospital, Cologne, Germany. PBMCs were prepared from
buffy coats by standard Ficoll-Paque (Amersham Pharmacia Bio-
tech) density gradient centrifugation. PDCs were isolated from
PBMCs by direct magnetic labeling with anti–BDCA-4 mAb
(AD5–17F6)–conjugated microbeads (BDCA-4 Cell Isolation
Kit; Miltenyi Biotec; reference 19) and enrichment of labeled
cells using a high-gradient magnetic cell sorting device (Mini-
MACS
 
®
 
; Miltenyi Biotec). As determined by staining with PE-
conjugated anti–BDCA-2 mAb (AC144; Miltenyi Biotec; refer-
ence 19) and flow cytometric analysis using a FACSCalibur™
(Becton Dickinson) and CELLQuest™ software (Becton Dickin-
son), PDC purities of 92–98% were routinely obtained.
For molecular cloning of BDCA-2, PDCs were isolated from
leukapheresis products by indirect magnetic labeling with FITC-
conjugated anti–BDCA-2 mAb (AC144; Miltenyi Biotec) and
anti-FITC mAb-conjugated microbeads (Miltenyi Biotec), fol-
lowed by enrichment of labeled cells using a clinically approved
immunomagnetic selection device (CliniMACS
 
®
 
; Miltenyi Bio-
tec). Leukapheresis products from nonmobilized volunteers were
obtained from the DRK-Blutspendezentrale Ulm, Ulm, Germany.
For reverse transcription (RT)-PCR analysis of BDCA-2
mRNA expression, T cells, B cells, NK cells, and monocytes
were isolated from PBMCs by cell sorting with a FACSVan-
tage™ (Becton Dickinson) using mAb against CD3 (mAb SK9,
IgG2b; Becton Dickinson), CD19 (mAb 4G7, IgG1; Becton
Dickinson), CD56 (mAb MY31, IgG1; Becton Dickinson), and
CD14 (mAb M
 
 
 
P9, IgG2b; Becton Dickinson), respectively.
Similarly, CD11c
 
 
 
 myeloid DCs and CD123
 
 
 
 PDCs were iso-
lated by FACS
 
®
 
 based on the absence of a panel of leukocyte
lineage-specific Ag (Lineage Cocktail 1 from Becton Dickinson
including mAb against CD3, CD14, CD16, CD19, CD20, and
CD56), and the presence of HLA-DR (mAb L243, IgG2a; Bec-
ton Dickinson) and either of CD11c (mAb S-HCL-3, IgG2b;
 
Becton Dickinson) or of CD123 (mAb 9F5, IgG1; Becton
Dickinson), respectively.
 
Expression Cloning of Full-length BDCA-2 cDNA.
 
Poly(A)
 
 
 
RNA was isolated from magnetically purified PDC using
Oligo(dT) microbeads and a high-gradient magnetic cell sorting
device (
 
 
 
MACS
 
®
 
 mRNA Isolation Kit; Miltenyi Biotec), and
used to construct a cDNA library in pEF18SR, a modified
pEF18S expression vector (40). Transient expression was per-
formed in COS1 cells. After several rounds of MACS
 
®
 
 and fi-
nally FACS
 
®
 
 using anti BDCA-2 mAb AC144 (19), plasmid
DNA of a positive clone (H4#10A) was purified and sequenced.
Homology searches were performed in GenBank/EMBL/DDBJ
nucleotide databases. Alignments with the murine DC-associ-
ated C-type lectin 2 (dectin-2; reference 41) and the human DC
immunoreceptor (DCIR; reference 42) and several other type II
C-type lectins were analyzed using the ALIGN function of the
Genestream server at the Institut de Génétique Humaine, Mont-
pellier, France.
 
RT-PCR Analysis.
 
For RT-PCR analysis of BDCA-2
mRNA expression in various blood cell populations, poly(A)
 
 
 
RNA was isolated from FACS
 
®
 
-purified human T cells, B cells,
NK cells, monocytes, CD11c
 
 
 
 myeloid blood DCs, and CD11c
 
 
 
PDCs. First-strand cDNA was prepared from isolated poly(A)
 
 
 
RNA by reverse transcription using Oligo(dT)12–18 primers
(Life Technologies) and the SuperScript II reverse transcriptase
(Life Technologies). For RT-PCR analysis of BDCA-2 mRNA
expression in various tissues (heart, brain, placenta, lung, liver,
skeletal muscle, kidney, pancreas, spleen, thymus, prostate, testis,
ovary, small intestine, LN, bone marrow, and fetal liver) sets of
normalized first-strand cDNA (Human Multiple Tissue cDNA
Panels I and II; CLONTECH Laboratories, Inc.) were used. All
cDNAs were normalized to several different housekeeping genes
(glyceraldehyde-3-phosphate dehydrogenase, phospholipase A2,
 
 
 
-tubulin, and 
 
 
 
-actin). PCR amplification (34 or 38 cycles) was
performed using AdvanTaq Plus DNA Polymerase (CLON-
TECH Laboratories, Inc.) and the primers 5
 
 
 
-TTG AAA GAA
CCA CAC CCC GAA AGT-3
 
 
 
 (forward primer) and 5
 
 
 
-TAG
CTT TCT ACA ACG GTG GAT GCC-3
 
 
 
 (reverse primer) un-
der the following conditions: 30 s denaturation at 94
 
 
 
C and 120 s
annealing and elongation at 68
 
 
 
C. The PCR products were size-
fractionated by agarose gel electrophoresis and analyzed after
ethidium bromide staining.
 
Cloning of Truncated BDCA-2 cDNAs (Splice Variants).
 
Puri-
fied Poly(A)
 
 
 
 RNA from PDCs was subjected to DNase I treat-
ment and BDCA-2 mRNA species were specifically amplified by
RT-PCR using the Titan One Tube RT-PCR-System (Roche
Diagnostics GmbH) and the primers 5
 
 
 
-ACA CAA TGG TGC
CTG AAG AAG-3
 
 
 
 (forward primer) and 5
 
 
 
-ACA TTT TAG
GGG CAT TCC TTG TA-3
 
 
 
 (reverse primer). After preincuba-
tion for 10 min at 25
 
 
 
C and for 30 min at 55
 
 
 
C, PCR cycles (20,
25, and 30 cycles) were run under the following conditions: 30 s
denaturation at 94
 
 
 
C, 45 s annealing at 57
 
 
 
C, and 90 s elongation
at 72
 
 
 
C. Amplified cDNA fragments were size-fractionated by
4–12% Tris-borate-EDTA (TBE) PAGE and analyzed after staining
with ethidium bromide. Individual bands were excised and sub-
jected to PCR reamplification (30 cycles) using the same primer
set and the same cycle conditions. After another round of size-
fractionation by 4–12% TBE PAGE and excision of the appropri-
ate bands, reamplified fragments were cloned and sequenced. To
confirm that two different truncated BDCA-2 mRNA species
lacking either exon 3 (665 bp) or exon 4 (647 bp) were present in
one excised band (Fig. 4), another round of PCR reamplification
(30 cycles; 30 s denaturation at 94
 
 
 
C, 60 s annealing at 60
 
 
 
C, and 
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60 s elongation at 72
 
 
 
C) was performed using two new sets of
primers that allow for amplification of only the variant lacking
exon 3 (forward primer binding in exon 2: 5
 
 
 
-ACA CAA TGG
TGC CTG AAG AAG-3
 
 
 
 and reverse primer binding in exon 4:
5
 
 
 
-TGG ACA GCC TCT TGA CAG TTT-3
 
 
 
) or the variant
lacking exon 4 (forward primer binding in exon 3: 5
 
 
 
-TGG CAG
TCG TAT CCA TCT TG-3
 
 
 
; reverse primer binding in exon 7:
5
 
 
 
-ACA TTT TAG GGG CAT TCC TTG TA-3
 
 
 
).
 
Immunohistological Localization/Characterization of BDCA-2–
expressing PDCs.
 
Immunohistochemical staining of air-dried,
acetone-fixed sections from LNs, tonsils, thymus, and testis with
anti–BDCA-2 mAb (AC144, IgG1) was done following an indi-
rect immunoperoxidase technique. Single-color immunofluores-
cent staining of acetone-fixed cryosections of lymph nodes and
thymus was done by primary staining with nonconjugated anti–
BDCA-2 mAb (AC144, IgG1) or CD123 mAb (7G3, IgG2a;
Becton Dickinson) and secondary staining with FITC-conjugated
anti–mouse IgG1 Ab (Southern Biotechnology Associates, Inc.)
and Texas red–conjugated anti–mouse IgG2a Ab (Southern Bio-
technology Associates, Inc.), respectively.
Double–color immunofluorescent staining of cryostat sections
of frozen human tonsils was performed using anti–BDCA-2-
FITC (AC144, IgG1) and nonconjugated mAb (IgG2) against
CD8, CD20, CD123, and HLA-DR, respectively. Staining with
nonconjugated primary mAb was revealed by secondary staining
with biotinylated anti-isotype mAb and Texas red–conjugated
streptavidin.
 
Immunoprecipitation.
 
Cells were surface labeled with 1 mCi of
Na
 
125
 
I using the sulfosuccinimidyl-3-(4-hydroxyphenyl)propi-
onate method (43). After surface labeling, cells were lysed in 1%
Triton X-100, 100 mM Tris-HCl, pH 7.4, 150 mM NaCl, 5
mM EDTA, 1 mM PMSF, 10 
 
 
 
g/ml aprotinin, and 10 
 
 
 
g/ml
leupeptin. After overnight preclearing with protein G-sepharose,
lysates were incubated with anti–BDCA-2 mAb (AC144, IgG1)
or isotype-matched control mAb at 
 
 
 
4
 
 
 
C for 4 h, and immune
complexes were precipitated by addition of protein G-Sepharose
for 1.5 h at 
 
 
 
4
 
 
 
C. Precipitates were washed three times with lysis
buffer, followed by a final wash with 10 mM Tris-HCl, pH 7.4,
15 mM NaCl, and then resuspended in nonreducing or reducing
sample buffer. SDS-PAGE analysis was performed according to a
standard procedure. After the run, gels were dried and exposed to
autoradiography film (Amersham Pharmacia Biotech) for 2–5 d.
 
Measurement of Cytosolic Calcium Concentrations ([Ca
 
2
 
 
 
]i).
 
PDCs, U937 cells, and BDCA-2–transfected U937 cells were
loaded with Indo-1 AM (Sigma-Aldrich) as described (44). In
stimulation experiments, anti–BDCA-2 mAb (AC144, IgG1) was
added to PDCs, U937 cells, and BDCA-2–transfected U937 cells,
respectively, followed by F(ab
 
 
 
)
 
2 
 
goat anti–mouse IgG (Milan An-
alytica) as cross-linker. Cells were then analyzed on a flow cyto-
fluorimeter (FACSVantage™; Becton Dickinson) to detect Ca
 
2
 
 
 
fluxes. Only live (based on forward scatter criteria) and Indo-1–
loaded cells (based on 405 nM versus 525 nM emission spectra)
were included in the analysis. To test whether a [Ca
 
2
 
 
 
]i increase
was dependent on extracellular Ca
 
2
 
 
 
, cells were stimulated in
buffer with excess EGTA (4 mM). To test whether a [Ca
 
2
 
 
 
]i in-
crease was dependent on src-family protein-tyrosine kinases, cells
were preincubated for 40 min with 20 
 
 
 
g/ml PP2 (Calbiochem).
 
Western Blotting.
 
For anti-phosphotyrosine blots, PDCs,
BDCA-2–transfected U937 cells, and BDCA-2–transfected Jur-
kat cells (10
 
6
 
) were incubated for 2 min at 37
 
 
 
C with medium or
with anti–BDCA-2 mAb (AC144, IgG1). Cells were washed in
ice-cold PBS and lysed in Laemmli protein sample buffer (0.06 M
Tris-HCl, pH 6.8, 2% SDS, 10% glycerine, 0.005% bromphenol
 
blue). Cell lysates were sonicated, boiled, separated by SDS-
PAGE, transferred to nitrocellulose, and probed with horseradish
peroxidase (HRP)-coupled anti-phosphotyrosine mAb PY20
(100 ng/ml; Becton Dickinson). Immunoblotted proteins were
visualized by chemiluminescence using enhanced chemilumines-
cence detection reagents (Amersham Pharmacia Biotech).
 
Ag Presentation Assay.
 
30,000 cells of the B13 T cell clone
(45) were cocultured with (a) 37,000, (b) 18,500, (c) 9,250, (d)
4,625, (e) 2,312, and (f) 1,156 irradiated PDCs (3,000 rad) in 96-
well flat-bottom microplates in the presence of 200 ng/ml of
IgG1 mAb. mAb used in the assay were the following: anti–
BDCA-2 (AC144, IgG1), anti–ILT3 (ZM3.8, IgG1), and anti-
cytokeratin (CK3–11D5, IgG1). After 48 h, the cultures were
pulsed with [
 
3
 
H]thymidine (1 
 
 
 
Ci/well, specific activity 5 Ci/
mmol), and the radioactivity incorporated was measured after ad-
ditional 16 h.
 
In Vitro Stimulation of PDCs.
 
Purified PDCs were cultured at
a cell density of 5 
 
 
 
 105 to 106 cells/ml in medium (RPMI 1640
supplemented with 2 mM L-glutamine, 10% FCS, 110 mg/liter
sodium pyruvate, 100 U/ml penicillin, and 100  g/ml strepto-
mycin) at 37 C in a humidified 5% CO2-containing atmosphere
in the presence of 10 ng/ml IL-3 (PeproTech) for 24 h. One of
the following agents was typically added for induction of IFN- / 
expression: (a) influenza A/PR8 virus (FLU, used at a final con-
centration of 5 hemagglutinating units/ml), (b) anti–single-
stranded (ss) and double-stranded (ds) DNA mAb MER-3 (Sero-
tec; dialyzed against RPMI 1640 and used at a final concentration
of 2.5  g/ml) plus plasmid pcDNA3 (used at a final concentra-
tion 0.5  g/ml), (c) sera from SLE patients (provided by Falk
Hiepe, Charite, Medical School of the Humboldt University,
Berlin, Germany, and used at a final dilution of 1/5), (d) CpG
oligonucleotides (AAC-30 and GAC-30; reference 14), and (e)
OK432, an immunomodulator derived from the Su strain of
Streptococcus pyogenes. To test the effect of triggering of BDCA-2
on the induction of IFN- /  expression, anti–BDCA-2 mAb
(AC144, IgG1) was added at a final concentration of 5  g/ml.
ELISA. The levels of IFN-  in culture supernatants were
determined by an ELISA kit (R&D Systems).
Results
BDCA-2 Is a Type II C-type Lectin. We used transient
expression cloning in COS1 cells to identify BDCA-2, the
molecule recognized by the PDC-specific mAb AC144
(19). A full-length 1,313 bp cDNA sequence was isolated
after transfection of COS1 cells with a cDNA library pre-
pared from purified PDCs. The cDNA contains a 491 bp
5  UTR, a 642 bp open reading frame, a 3  UTR of 150
nucleotides, and a poly(A) tail of 30 bp (GenBank/
EMBL/DDBJ accession no. AF293615). The open read-
ing frame predicts a novel polypeptide of 213 amino acids
(Fig. 1) with a molecular mass of 25.021 kD. The pres-
ence of a hydrophobic signal anchor (residues 22–41) in-
dicates a type II transmembrane protein. BDCA-2 belongs
to the Ca2 -dependent (C-type) lectin family with a sin-
gle carbohydrate recognition domain (CRD; Fig. 1) fea-
turing a glutamate-proline-asparagine (EPN) motif (posi-
tion 172–174) predicting mannose-type specificity (46).
Three potential N-glycosylation sites are present at posi-
tions 110–113, 137–140, and 164–167 amino acids, re-
spectively. Finally, BDCA-2 contains an intracellular1826 BDCA-2, a PDC-specific Type II C-type Lectin
domain of 21 amino acids without any known motif im-
plicated in signal transduction.
Amino acid sequence comparison in the GenBank and
EMBL databases revealed marked homology between
BDCA-2 and several type II C-type lectins, especially in
the CRD. BDCA-2 displays highest homology with mu-
rine dectin-2 (50.7% amino acid identity in the overall se-
quence; reference 41) and human DCIR (42.1% amino
acid identity in the overall sequence; reference 42; Fig. 1).
Genomic Structure and Chromosomal Localization of the
Human BDCA-2 Gene. Due to complete nucleotide se-
quence identity over seven stretches between the BDCA-
2–encoding cDNA and sequences of genomic DNA frag-
ments present in the Genbank database (GenBank/EMBL/
DDBJ accession no. AC006517: clone RP11–277J24,
working draft sequence, 21 unordered pieces), the human
BDCA-2 gene could be mapped to the short arm of chro-
mosome 12. Furthermore, by analyzing the ends of the
seven sequence identity stretches (the putative exon-intron
boundaries) for the presence of conserved splice donor
(5 (C/A)AG-GU(A/G)AGU) and acceptor sites (5 (U/
C)11N(U/C)AG-(G/A)) (47), and by sequencing a series
of truncated BDCA-2 mRNA species (see below), the
number of exons in the full-length BDCA-2 mRNA as
well as the precise positions of intron excisions, could be
deduced. The full-length BDCA-2 mRNA consists of
seven exons, with exon 1 (1–361 bp) representing most of
the 5  UTR, exon 2 (362–522 bp) encoding 10 amino ac-
ids of the cytoplasmic domain, exon 3 (523–615 bp) en-
coding 31 amino acids mainly in the transmembrane do-
main, exon 4 (616–726 bp) encoding 37 amino acids
mainly in the neck domain, exon 5 (727–872 bp) encoding
49 amino acids mainly in the CRD, exon 6 (873–988 bp)
encoding 39 bp in the CRD, and exon 7 (989–1283 bp)
encoding 47 bp in the CRD. The overall exon-intron or-
ganization of BDCA-2 and dectin-2 (41) are virtually iden-
tical, suggesting that dectin-2 may indeed represent the
murine homologue of human BDCA-2 rather than the ho-
mologue of any other human C-type lectin.
BDCA-2 Is Selectively Expressed in PDCs. Using first-
strand cDNA from multiple tissues and blood leukocyte
populations for analyzing BDCA-2 mRNA expression by
PCR (34 cycles, forward primer in the 5 UTR and a re-
verse primer in the 3 UTR), BDCA-2 transcripts were
easily detectable in purified PDCs, but not detectable in
all other tested blood leukocyte populations, including
CD11c  myeloid DCs, and in all tested tissues (Fig. 2).
This finding provides evidence that other cells than PDCs
most likely do not express BDCA-2 mRNA. On the other
hand, this finding also raises the question of whether PDCs
in tissues do not express BDCA-2 or whether the PCR
analysis has not been sensitive enough to detect PDC-
derived BDCA-2 mRNA in first-strand cDNA from whole
tissues. To further analyze this, four more PCR cycles (38
instead of 34) were used for PCR amplification of BDCA-2
mRNA. Indeed, using four more PCR cycles, weak
BDCA-2 mRNA signals were also detectable in some but
not all tissues (tonsil, bone marrow, pancreas, testis, and
ovary; data not shown). To analyze to which degree
BDCA-2 mRNA expression in these tissues might be at-
tributable to presence of BDCA-2–expressing PDCs, sec-
tions from several tissues were stained with anti–BDCA-2
mAb. Double-staining of sections from tonsils for BDCA-2
(green) and CD8, CD20, CD123, or HLA-DR (red), re-
spectively, revealed that BDCA-2 expression is completely
restricted to CD123 HLA-DR CD8 CD20  PDCs. In
fact, confirming previous observations about the localiza-
tion of PDCs in tonsils (18), BDCA-2 CD123 HLA-
DR CD8 CD20  PDCs were found in the T cell–rich
extrafollicular areas but not within germinal centers (Fig.
3). Anti–BDCA-2 mAb also strongly labeled large clusters
Figure 1. Amino acid sequence alignment of the
type II C-type lectins BDCA-2, murine dectin-2,
and human DCIR. Identical or conserved residues
are indicated by (*), conserved and semiconserved
substitutions by (:) and (.), respectively; the puta-
tive transmembrane domains are shown in red ital-
ics; the shaded area denotes the CRD and the resi-
dues strongly conserved among C-type lectins are
shown in bold type (H, hydrophobic; A, aliphatic;
C, cysteine; G, glycine; E, glutamic acid; W, tryp-
tophan;  , aromatic;  , involved in calcium-
dependent binding of carbohydrate;  P  ,
so-called EPN-motif predicting mannose-type
specificity [reference 46]).
Figure 2. Expression analysis of BDCA-2 mRNA by RT-PCR (34
PCR-cycles) on various tissues and cell populations (1, heart; 2, brain;
3, placenta; 4, lung; 5, liver; 6, skeletal muscle; 7, kidney; 8, pancreas;
9, spleen; 10, thymus; 11, testis; 12, ovary; 13, small intestine; 14, LN;
15, bone marrow; 16, fetal liver; 17, tonsil; 18, T cells; 19, B cells; 20,
NK cells; 21, monocytes; 22, CD11cbrightCD123low myeloid DCs (refer-
ence 19); 23, CD11c CD123bright PDCs). All cDNAs were normalized
using four housekeeping genes including glyceraldehyde 3-phosphate
dehydrogenase (G3PDH).1827 Dzionek et al.
of CD123  PDCs occurring in reactive LN (data not
shown). Interestingly, whereas most if not all PDCs in ton-
sils and LNs were found to coexpress BDCA-2 and
CD123, high endothelial venules (HEVs) were CD123 ,
but completely negative for BDCA-2 (Fig. 2). Similarly,
by immunohistochemical staining of serial sections of nor-
mal human thymus, PDCs in thymus were also found to
coexpress BDCA-2 and CD123. However, it should be
noted that anti–BDCA-2 mAb also stained a considerable
proportion of cortical thymocytes, whereas CD123 was
totally negative on these cells (data not shown). Whether
this is due to some cross-reactivity of anti–BDCA-2 mAb
AC144 with molecules on cortical thymocytes or whether
positive staining indeed reflects BDCA-2 expression on
cortical thymocytes is currently under investigation. Im-
munohistochemical analysis of testis obtained from patients
with seminoma clearly shows that neoplastic and normal
epithelium are not stained for BDCA-2, but BDCA-
2 CD123  cells displaying a PDC morphology are regu-
larly detectable in association with lymphoid aggregates,
that typically occur in this tumor. As commercial first-
strand cDNA is not necessarily derived from tissue of
healthy donors, this indicates that the presence of BDCA-2
mRNA in the commercial first-strand cDNA from testis
(obtained from CLONTECH Laboratories, Inc.) may be
attributable to the presence of infiltrating PDCs, rather
than attributable to BDCA-2 mRNA expression by nor-
mal testis tissue. The same might also be true for pancreas,
ovary, and bone marrow.
Identification of Truncated BDCA-2 Transcripts Probably
Generated by Alternative Splicing. We detected some size
heterogeneity among the PCR-amplified BDCA-2 tran-
scripts. Apart from a band of  750 bp (full-length BDCA-2
mRNA), at least four additional bands of smaller size
were detected (Fig. 4), suggesting the presence of different
BDCA-2 mRNA species. This possibility was tested by
cloning and sequencing of PCR-amplified BDCA-2
mRNA. At least five truncated BDCA-2 mRNA species
that probably represent splice variants were identified (Fig.
4). These are variants lacking (a) exon 3, (b) exon 4, (c)
exon 5 (d) exon 3 and 4, and (e) exon 3 and 5. If translated,
these putative splice variants would give rise to isoforms of
BDCA-2 lacking (a) the transmembrane domain, (b) the
neck domain, (c) the whole CRD (lack of exon 5 results in
a frame shift which produces a termination codon in exon
6), (d) the transmembrane as well as the neck domain, and
(e) the transmembrane as well as the whole CRD.
Apparent Molecular Mass of BDCA-2. To define the
biochemical characteristics of BDCA-2, we performed im-
munoprecipitations from 125I surface-labeled PDCs and
Figure 3. Anatomical localization of BDCA-2–expressing PDCs in inflamed tonsils. Fluorescent double staining with FITC–conjugated (green) anti–
BDCA-2 mAb and Texas Red–conjugated (red) CD8 mAb (A), CD20 mAb (B), CD123 mAb (C), and anti–HLA-DR mAb (D). Note that BDCA-2–
expressing PDCs are found in the T cell-rich extrafollicular areas but not within the germinal center. Like CD123, BDCA-2 is expressed on PDCs, but
unlike CD123, BDCA-2 is not expressed on HEVs. One representative experiment of three is shown.1828 BDCA-2, a PDC-specific Type II C-type Lectin
BDCA-2–transfected U937 cells. A prominent band of
 38 kD was detected in all BDCA-2  cells under nonre-
ducing and reducing conditions (Fig. 5). The difference be-
tween the apparent molecular weight and the molecular
mass predicted from the full-length amino acid sequence
(25.021 kD), most likely results from N-glycosylation at
the N-glycosylation sites (see above). The presence of at
least one (PDCs and BDCA-2–transfected U937 cells) or
even of two (only PDCs) additional less prominent bands
of  85 kD and  45 kD, respectively, under nonreducing
and reducing conditions, could be due to formation of
SDS-stable dimers (85-kD band), differential glycosylation
or the presence of coimmunoprecipitated adaptor proteins.
Intracellular Calcium Mobilization after Anti–BDCA-2 mAb
Labeling. The possibility that anti–BDCA-2 mAb labeling
of PDCs results in signal trunsduction was first addressed by
measuring cytosolic calcium concentrations ([Ca2 ]i) in
PDCs and BDCA-2–transfected U937 and Jurkat cells be-
fore and after anti–BDCA-2 mAb labeling. As shown in
Fig. 6 B, ligation of surface BDCA-2 with a specific mAb
followed by a secondary cross-linking Ab elicited a rapid
and transient rise in [Ca2 ]i in PDCs and BDCA-2–trans-
fected U937 cells, but not in BDCA-2–transfected Jurkat
cells (data not shown) and nontransfected U937 cells. This
[Ca2 ]i increase was not affected when extracellular cal-
cium was chelated with excess EGTA (Fig. 6 C), indicating
that the [Ca2 ]i increase is due to intracellular calcium re-
lease. Interestingly, the [Ca2 ]i increase was much less pro-
nounced when src-family protein-tyrosine kinases were
blocked by preincubation with the specific inhibitor PP2
(Fig. 6 D).
Protein-Tyrosine Phosphorylation after Ligation of BDCA-2
with Specific mAb. To test whether intracellular calcium
mobilization was paralleled by protein-tyrosine phosphor-
ylation, we performed antiphosphotyrosine immunoblot-
ting on whole cell lysates of purified PDCs, BDCA-2–
transfected U937 cells, and BDCA-2–transfected Jurkat
cells before and after stimulation with anti–BDCA-2
mAb. As shown in Fig. 7, PDCs and BDCA-2 transfected
U937 cells triggered via BDCA-2 displayed a substantial
increase in overall protein-tyrosine phosphorylation, as
compared with nonstimulated PDCs and BDCA-2–trans-
fected U937 cells, respectively. Like the [Ca2 ]i (see
above), overall protein-tyrosine phosphorylation is not at
all affected by BDCA-2 triggering in BDCA-2–trans-
fected Jurkat cells. This is definitely not due to lack of sur-
face expression of BDCA-2 in Jurkat cells, but may rather
be due to lack of an adaptor protein functioning in
BDCA-2 signal transduction.
BDCA-2 on PDCs Is Able to Rapidly Internalize and De-
liver Anti–BDCA-2 mAb into an Ag-processing Compart-
ment. We have previously shown that labeling of BDCA-2
on PDCs by anti–BDCA-2 mAb and incubation at 37 C
induces rapid internalization of the Ag–mAb complex (19).
Interestingly, the same is not true for BDCA-2–transfected
U937 and Jurkat cells. When BDCA-2–transfected U937
and Jurkat cells were labeled with FITC-conjugated anti
BDCA-2 mAb AC144 (IgG1) and incubated for various
periods of time at 37 C to allow internalization, the
amount of AC144 mAb remaining on the cell surface as
determined by staining with PE-conjugated rat anti–mouse
Figure 4. (A) Identification of putative alternative splice forms of
BDCA-2 mRNA. Poly(A)  RNA was isolated from purified PDCs and
analyzed for the presence of BDCA-2 mRNA by RT-PCR amplification
(lane 2, 20 PCR cycles; lane 3, 25 PCR cycles; lane 4, 30 PCR cycles).
The PCR products were size-fractionated by 4–12% TBE PAGE. A fur-
ther PCR amplification of individual excised bands enabled the cloning
and sequencing of individual splice variants. (B) Schematic drawing of the
coding region of full-length BDCA-2 mRNA. The structural domains
are indicated by different colors (violet, cytoplasmic domain; red, trans-
membrane domain; green, neck domain; and blue, CRD) and the indi-
vidual exons (exons 2–7) of the coding region are represented as boxes.
Below the full-length BDCA-2 mRNA, BDCA-2 splice variants are
shown with the missing exons indicated by gaps.
Figure 5. SDS-PAGE analysis of BDCA-2 immunoprecipitated from
125I-labeled PDC (A) and BDCA-2–transfected U937 human monocy-
toid leukemia cells (B). BDCA-2 appears as a  38 kD band under nonre-
ducing (NR) and reducing (R) conditions. IC, isotype-matched control
mAb. One representative experiment of three is shown.1829 Dzionek et al.
IgG1 mAb did not decrease over time but remained con-
stant (data not shown).
To further investigate a possible role of BDCA-2 on
PDCs in Ag capture and Ag presentation, we analyzed the
ability of purified PDCs to present AC144 mAb to a CD4 
MHC class II–restricted T cell clone specific for a mouse
IgG1-derived peptide epitope (45). As controls, an IgG1
mAb that binds to ILT3 (ZM3.8), a receptor on PDCs
known to be capable of delivering its ligand to an intracel-
lular compartment where class II loading occurs (48), and
an IgG1 mAb that does not bind to surface molecules on
PDCs (anti-cytokeratin mAb CK3–11D5) were used. As
shown in Fig. 8, PDCs present AC144 mAb to T cells
more efficiently than the anti-ILT3 mAb ZM3.8 and far
more efficiently than anti-cytokeratin mAb CK3–11D5.
This indicates that BDCA-2 can efficiently deliver its
ligand into an Ag-processing compartment.
Ligation of BDCA-2 Inhibits Induction of IFN- /  Expres-
sion in PDCs. PDCs produce large amounts of IFN- / 
when stimulated in vitro with (a) viruses (3–8, 10, 21, 49,
50), (b) bacteria (51) (c) bacterial DNA (oligonucleotides)
containing particular unmethylated CpG motifs (CpG-
DNA) (14, 22), (d) dsRNA (poly(I:C)) (22), (e) sera from
patients with SLE containing an IFN- / –inducing factor
(most likely complexes of anti-DNA Ab and immunostim-
ulatory hypomethylated DNA (52, 53), or (f) complexes of
anti–double-stranded DNA mAb and unmethylated plas-
mid DNA (human anti-ss/ds DNA mAb MER-3 plus plas-
mid pcDNA3) mimicking the IFN- / –inducing factor
present in sera from SLE patients (53). We tested whether
in vitro induction of IFN- /  expression in purified PDCs
by FLU, anti-ss/ds DNA mAb MER-3 plus plasmid
pcDNA3, and sera from SLE patients is influenced by anti–
BDCA-2 mAb labeling of PDCs. As shown in Fig. 9 A,
coincubation of purified PDCs with the IFN- / –induc-
ing agents and anti–BDCA-2 mAb AC144 (IgG1), but not
a nonbinding control IgG1 mAb, dramatically inhibited in-
duction of IFN- /  expression as compared with incuba-
Figure 6. A rapid and transient
rise in [Ca2 ]i is induced in PDCs
(left dotplots) and BDCA-2-
transfected U937 cells (middle
dotplots), but not in nontrans-
fected U937 cells (right dotplots)
after ligation of surface BDCA-2
with specific primary mAb
(AC144, IgG1) and secondary
cross-linking F(ab )2 goat anti–
mouse IgG (B). This [Ca2 ]i in-
crease is not affected when extra-
cellular calcium is chelated with
excess EGTA (C), but inhibited
when src-family protein-tyrosine
kinases are blocked by preincu-
bation with the specific inhibitor
PP2 (D). One representative ex-
periment of six is shown.
Figure 7. Triggering of BDCA-2 induces protein tyrosine phosphory-
lation in purified PDCs (A) and BDCA-2 transfected U937 cells (B), but
not in BDCA-2–transfected Jurkat cells (C). Cells were incubated with
medium alone ( ) or with anti–BDCA-2 mAb (AC144, IgG1) ( ). Cell
lysates were size-fractionated by SDS-PAGE, transferred to nitrocellulose
membranes, and probed with horseradish peroxidase-coupled antiphos-
photyrosine mAb PY20. One representative experiment of two is shown.1830 BDCA-2, a PDC-specific Type II C-type Lectin
tion of PDCs with the IFN- / –inducing agents alone.
Similar results were obtained using CpG oligodeoxynucle-
otides (AAC-30 and GAC-30) and a killed streptococcal
preparation (OK432) for induction of IFN- /  expression
in PDCs (data not shown). Interestingly, with most IFN-
 / –inducing agents (e.g., anti ss/ds DNA mAb MER-3
plus plasmid pcDNA3 or sera from SLE patients), we re-
producibly obtained complete or nearly complete blocking
of induction of IFN- /   expression by anti–BDCA-2
mAb, whereas only partial blocking was obtained using
FLU as IFN- / –inducing agent. Titration of the anti–
BDCA-2 mAb (Fig. 9 B) reveals that concentrations below
100 ng/ml are sufficient for a 50% inhibition of the IFN-
 /  response to anti-ss/ds DNA mAb MER-3 plus plas-
mid pcDNA3. To check whether anti–BDCA-2 mAb in-
hibits induction of IFN- /  expression simply by PDC
killing or by induction of PDC maturation, we compara-
tively analyzed total numbers of viable PDCs and expres-
sion of several leukocyte Ag (CD83, CD80, CD86, etc.)
after various periods of culturing of PDCs in the presence
or absence of anti–BDCA-2 mAb. No significant differ-
ences were found (data not shown).
Discussion
DCs constitute a heterogeneous population of cells with
different developmental pathways and maturation stages.
While several leukocyte surface Ag, including costimula-
tory molecules, chemokine receptors, endocytic/phago-
cytic receptors, and typical DC activation/maturation Ag
are differentially regulated during DC maturation (54),
their expression is not restricted to DCs. Surface Ag re-
stricted to DC subsets, such as PDCs, however, are highly
valuable tools for cell monitoring in healthy volunteers and
patients. We have previously demonstrated that BDCA-2 is
an excellent marker for the identification of PDCs in blood
(19). The present study extends this finding to lymphoid
(LNs, tonsils, thymus) and nonlymphoid (testis) tissue. In
line with the Ab staining data, our RT-PCR analysis also
indicates a strict restriction of BDCA-2 mRNA expression
to PDCs.
DCs are found to express a huge number of lectins that
appear to serve quite distinct functions. Members of the
C-type lectin family can be divided into two groups based
on their molecular structures: (a) type I surface lectins with
multiple CRD in the NH2-terminal extracellular region,
and (b) type II surface lectins with a single CRD in the
COOH-terminal extracellular region. DC express type I as
well as type II lectins. Endocytic activity, a hallmark of re-
ceptor-mediated uptake of Ag, is exhibited by type I multi-
CRD lectins, such as the macrophage-mannose receptor
(MMR; reference 55) and DEC-205 (56), as well as by
type II single-CRD lectins, such as CD23 (57) and Lan-
gerin (58). Langerin is specifically expressed by Langerhans
cells, whereas the MMR, CD23, and DEC-205 are not
specifically expressed by DCs in general or by a particular
DC subset. Our data indicate that BDCA-2 is a unique en-
docytic type II single-CRD lectin specifically expressed in
Figure 8. Presentation of anti–BDCA-2 mAb (AC144, IgG1) to a T
cell clone specific for mouse IgG1 by irradiated PDCs. Anti–BDCA-2
mAb AC144 ( ) is presented more efficiently than anti-ILT3 mAb
ZM3.8 ( ) and far more efficiently than anti-cytokeratin mAb CK3–11D5
( ). One representative experiment of two is shown.
Figure 9. (A) Ligation of BDCA-2 suppresses induction of IFN- / 
production in PDCs. Stimulation of PDCs with FLU, anti-ss/ds DNA
mAb MER-3 plus plasmid pcDNA3, or serum from a SLE patient, but
not with anti-ss/ds DNA mAb MER-3 alone or plasmid pcDNA3 alone,
induces production of large amounts of IFN- /  in PDCs. Induction of
IFN- /  production with this agents can be inhibited by coincubation
with anti–BDCA-2 mAb (AC144, IgG1), but not by coincubation with
an isotype-matched control IgG1 mAb. The data shown are representa-
tive of more than six experiments using FLU, more than two experiments
using anti-ss/ds DNA mAb MER-3 plus plasmid pcDNA3, and three ex-
periments using SLE sera as IFN- /  production–inducing agent. (B)
Anti–BDCA-2 mAb-mediated suppression of induction of IFN- /  pro-
duction is mAb concentration dependent. Purified PDCs were coincu-
bated with one of the IFN- / –inducing agents (anti-ss/ds DNA mAb
MER-3 plus plasmid pcDNA3) and titrated amounts of anti–BDCA-2
mAb (AC144, IgG1). Note that concentrations below 100 ng/ml are suf-
ficient for a 50% inhibition of the IFN- /  response.1831 Dzionek et al.
PDCs and able to target ligand into Ag processing and pep-
tide-loading compartments for presentation to T cells.
In addition to its Ag-capturing function, BDCA-2 can
mediate potent inhibition of induction of IFN- /  expres-
sion in PDCs. Production of IFN- /  in response to sev-
eral different types of viruses (3–8, 10, 21, 50), bacteria
(51), CpG-DNA (14, 22), dsRNA (22), and SLE serum
(52, 53) is by far the most prominent feature of PDCs. It
has recently been shown that PDCs express high amounts
of toll-like receptor 9 (TLR9; reference 59) and that TLR9
confers responsiveness to CpG-DNA (60). Thus, TLR9 is
a prime candidate for mediating induction of IFN- /  ex-
pression in PDCs, but, in the light of the wide variety of
IFN- / –inducing agents, other receptors are likely to
serve the same function. Our data show that triggering of
BDCA-2 can potently inhibit in vitro induction of IFN- / 
expression in PDCs by (a) viruses, (b) the combination of
anti-dsDNA mAb and unmethylated plasmid DNA, (c)
SLE serum, (d) CpG oligonucleotides, and (e) OK432. The
diversity of IFN- / –inducing agents makes it anyway
highly unlikely that anti–BDCA-2 mAb AC144 simply
blocks binding of the IFN- / –inducing agents to PDCs,
but this can also be ruled out by the fact that induction of
IFN- /  expression is also suppressed if the IFN- / –
inducing agent is added 1 h before the anti–BDCA-2 mAb
(data not shown).
SLE patients have increased levels of IFN- /  in the cir-
culation and increased production of IFN- /  may well be
of pathogenic significance in SLE (61–63). This is strongly
supported by the observation that IFN- /  therapy of pa-
tients with nonautoimmune diseases occasionally induces
the development of Ab against dsDNA and SLE-like syn-
dromes (64-67). PDCs have been proposed to be a major
source of IFN- /  in SLE (52), but the observation that
SLE patients have a reduced number of PDCs in peripheral
blood (68) seemed to contradict this hypothesis. However,
recent studies by Farkas et al. (35) and Blomberg et al. (34)
have demonstrated accumulation of PDCs in cutaneous
SLE lesions. This indicates that the low numbers of PDC in
blood are due to their increased recruitment to tissues. Fur-
thermore, by showing that the density of PDCs in affected
skin correlated well with the number of cells expressing the
IFN- / –inducible protein MxA, Farkas et al. (35) pro-
vided strong evidence that PDCs are indeed a major source
of IFN- /  in SLE. Based on our in vitro results it appears
reasonable to evaluate a novel strategy for inhibiting IFN-
 /  production by PDCs in SLE patients, namely by
means of in vivo administration of anti–BDCA-2 mAb.
BDCA-2 showed the highest degree of homology to
murine dectin-2 (50.7% amino acid identity in the overall
sequence; reference 41) and to human DCIR (42.1%
amino acid identity in the overall sequence; reference 42).
BDCA-2 and dectin-2 differ from DCIR in that the im-
munoreceptor tyrosine-based inhibitory motif (ITIM)
found in the intracellular domain of DCIR was absent
from the relatively short intracellular domains of dectin-2
(14 amino acids) and BDCA-2 (21 amino acids). The intra-
cellular domains of BDCA-2 and dectin-2 also lack an im-
munoreceptor tyrosine based activation motif (ITAM) and
any other known motif implicated in signal transduction.
Based upon these observations, Ariizumi et al. (41) con-
cluded that dectin-2 has no signaling potential. We found
that triggering of BDCA-2 induces src-family protein-tyro-
sine kinase–dependent intracellular calcium mobilization
and protein-tyrosine phosphorylation of intracellular pro-
teins. Thus, though no apparent signaling motif is present
in the intracellular domain of BDCA-2, BDCA-2 clearly is
a signaling receptor that activates protein-tyrosine kinases.
Previous studies on the regulation of IFN- /  production
in PDCs indicate that activation of protein kinases may
play a direct role in the BDCA-2–mediated inhibition of
IFN- /  induction (69, 70). It remains to be analyzed
whether signaling is accomplished by the pairing of
BDCA-2 with a signaling membrane adaptor molecule,
such as DAP12. DAP12 associates noncovalently with a
large number of receptors in natural killer and myeloid
cells, including several membrane glycoproteins of the
C-type lectin superfamily. All associations are based on the
presence of a negatively charged residue in the transmem-
brane domain of DAP12 and a positive charge in the trans-
membrane domain of the receptor (71, 72). As positively
charged amino acid residues are not present in the trans-
membrane domain of BDCA-2, it is rather unlikely that
DAP12 itself associates with BDCA-2.
Unfortunately, no information is currently available on
the natural ligands and the carbohydrate specificities of
DCIR, dectin-2, and BDCA-2. In fact, a His-tagged re-
combinant protein containing the extracellular domain of
dectin-2 showed no specific binding to any of a panel of
carbohydrate probes (41). Future studies are required to
identify the ligand(s) of BDCA-2.
In this context, it may also be worth mentioning that at
least five different truncated BDCA-2 transcripts, which are
most likely generated by alternative splicing, have been
identified. If these truncated BDCA-2 transcripts are trans-
lated, all of them completely lack one or two structural
components: the transmembrane domain alone, the neck
domain alone, the CRD alone, the transmembrane domain
and the neck domain, or the transmembrane domain and
the CRD. Two truncated isoforms have also been identi-
fied for dectin-2, one with a 34 amino acids deletion in the
neck domain and one with a 41 amino acids deletion
within the CRD (41). Isoforms lacking the transmembrane
domain might serve as soluble receptors controlling mem-
brane-bound receptor-mediated functions.
In conclusion, in this study, we report the molecular
cloning and functional characterization of BDCA-2, a
novel lectin specifically expressed by PDCs. Remarkably,
BDCA-2 is a PDC-specific transmembrane lectin that ap-
pears to display a dual function of Ag-capturing and potent
inhibition of IFN- /  induction. As production of IFN-
 /  by PDCs has been implicated to play an important
role in innate antiviral immunity (21) and Th1 polarization
(20), triggering of BDCA-2 may be critical for skewing T
cell responses toward a non-Th1 type of response and en-
able viruses to escape from the host immune defense.1832 BDCA-2, a PDC-specific Type II C-type Lectin
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